Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day, the company announced through an exchange filing.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
'Heartbreaking': Taapsee Pannu Reacts To Influencer Misha Agarwal's Suicide After Losing Instagram Followers
West Bengal CM Mamata Banerjee Announces ₹2 Lakh Relief After 14 Die In Fire At Kolkata’s Rituraj Hotel
‘Bro Thinks He’s Ronaldo’: Rizwan, Donning Pepsi Logo Jersey, Trolled For Peeling Off Sponsor's Label From Bottle; Video Viral
Waves 2025: Shah Rukh Khan, Allu Arjun, Deepika Padukone, Alia Bhatt & More Indian Celebs Are All Set To Attend The Summit - Deets Inside
